Soluble interleukin-2 receptor (sIL-2R) is a marker of disease activity in psoriasis: A comparison of sIL-2R, sCD27, sCD4, sCD8 and sICAM-1

Acta Dermato-Venereologica

Volumn 76, Issue 5, 1996, Pages 357-360

  De Rie, Menno A ^a   Zonneveld, Ingrid M ^a   Witkamp, Leonard ^a   Van Lier, René A W ^a   Out, Theo A ^a   Bos, Jan D ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

CD25; Immunodermatology; T lymphocytes

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYCLOSPORIN A; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2 RECEPTOR; TACROLIMUS;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PSORIASIS;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD27; ANTIGENS, CD4; ANTIGENS, CD8; BIOLOGICAL MARKERS; CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERCELLULAR ADHESION MOLECULE-1; MIDDLE AGED; MONITORING, PHYSIOLOGIC; PSORIASIS; RECEPTORS, INTERLEUKIN-2; SEVERITY OF ILLNESS INDEX; TACROLIMUS;

EID: 0029795357     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Bos JD. The pathomechanisms of psoriasis: the skin immune system and cyclosporine. Br J Dermatol 1988; 118: 141-155.
2. Nicolas J-F, Chamchick N, Thivolet J, Wijdenes J, Morel P, Revillard JP. CD4 antibody treatment of severe psoriasis. Lancet 1991; 338: 321.
3. Meingassner JG, Stutz A. Immunosuppressive macrolides of the type FK506: a novel class of topical agents for treatment of skin diseases. J Invest Dermatol 1992; 98: 851-855.
4. Valdimarsson H, Baker BS, Jónsdóttir I, Powles A, Fry L. Psoriasis: a T-cell-mediated autoimmune disease induced by streptococcal superantigens? Immunol Today 1995; 16: 145-149.
5. Smith KA, Cantrell DA. Interleukin 2 regulates its own receptors. Proc Natl Acad Sci USA 1985; 82: 864-868.
6. De Jong R, Loenen WAM, Brouwer M, Van Emmerik L, De Vries EFR, Borst J, et al. Regulation of expression of CD27, a T cell-specific member of a novel family of membrane receptors. J Immunol 1991; 146: 2488-2494.
7. + T cell subset. Eur J Immunol 1988; 18: 811-816.
8. Hintzen RQ, De Jong R, Lens SMA, Van Lier RAW. CD27: marker and mediator of T-cell activation? Immunol Today 1994; 15: 307-311.
9. De Rie MA, Hamerlinck F, Hintzen RQ, Bos JD, Van Lier RAW. Quantitation of soluble CD27, a T-cell activation antigen, and soluble interleukin-2 receptor in serum from patients with psoriasis. Arch Dermatol Res 1991; 283: 533-534.
10. Schopf RE, Höcher J, Schütz N, Färber L, Morsches B. Psoriasis treatment with etretinate versus cyclosporin A. Clinical course and serum concentrations of soluble interleukin-2 receptors and CD8 antigen. Eur J Dermatol 1992; 2: 224-230.
11. Baker BS, Swain AF, Fry L, Valdimarsson H. Epidermal T lymphocytes and HLA-DR expression in psoriasis. Br J Dermatol 1984; 11: 555-564.
12. De Rie MA, Cairo I, Van Lier RAW, Bos JD. Expression of the T-cell activation antigens CD27 and CD28 in normal and psoriatic skin. Clin Exp Dermatol, in press.
13. Gearing AJH, Newman W. Circulating adhesion molecules in disease. Immunol Today 1993; 14: 506-512.
14. Schopf RE, Naumann S, Render M, Morsches B. Soluble intercellular adhesion molecule-1 levels in patients with psoriasis. Br J Dermatol 1993; 128: 34-37.
15. Carducci M, Mussi A, Bonifati C, Fazio M, Ameglio F. sICAM-1. sIL-2R and beta2-microglobulin serum levels in patients affected with psoriasis: relationship with disease severity. Arch Dermatol Res 1994; 286: 420-421.
16. Elias AN, Goodman MM, Rohan MK. Serum ICAM-1 concentrations in patients with psoriasis treated with antithyroid thioureylenes. Clin Exp Dermatol 1993; 18: 526-529.
17. De Rie MA, Meinardi MMHM, Bos JD. Analysis of side-effects of medium and low-dose cyclosporin maintenance therapy in psoriasis. Br J Dermatol 1990; 123: 347-353.
18. European FK506 Multicentre Psoriasis Study Group. Systemic tacrolimus (FK506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. Arch Dermatol 1996; 132: 419-423.
19. Witkamp L, Meinardi MMHM, Bossuyt PMM, Van de Kerkhof PCM, Arnold WP, De Hoop D, et al. A multicentre evaluation of the guidelines for the use of cyclosporin A in severe psoriasis. J Eur Acad Dermatol Venereol, in press.
20. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978; 157: 238-244.
21. Hintzen RQ, Van Lier RAW, Kuijpers KC, Baars PA, Schaasberg W, Lucas CJ, et al. Elevated levels of a soluble form of the T cell activation antigen CD27 in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 1991; 35: 211-217.
22. Lisby S, Ralfkiaer E, Rothlein R, Vejlsgaard GL. Intercellular adhesion molecule-1 (ICAM-1) expression correlated to inflammation. Br J Dermatol 1989; 120: 479-484.
23. Rubin LA, Nelson DL. The soluble interleukin-2 receptor: biology, function and clinical application. Ann Intern Med 1990; 113: 619-627.
24. Kapp A, Piskorski A, Schöpf A. Elevated levels of interleukin 2 receptor in sera of patients with atopic dermatitis and psoriasis. Br J Dermatol 1988; 119: 707-710.
25. Kemmett D, Symons JA, Colver GB, Duff GW. Serum-soluble interleukin 2 receptor in psoriasis. Acta Derm Venereol (Stockh) 1990; 70: 264-267.
26. Takematsu H, Tagami H. Interleukin 2, soluble interleukin 2 receptor, and interferon-gamma in the suction blister fluids from psoriatic skin. Arch Dermatol Res 1990; 282: 149-152.
27. Cooper KD, Baadsgaard O, Ellis CN, Duell E, Voorhees JJ. Mechanisms of cyclosporine. Inhibition of antigen presenting activity in uninvolved and lesional psoriatic epidermis. J Invest Dermatol 1990; 94: 649-656.
28. Sigal NH, Lin CS, Siekierka JJ. Inhibition of human T-cell activation by FK506, rapamycin, and cyclosporin A. Transplant Proc 199; 23: Suppl 2: 1-5.
29. + B lymphocyte subset. J Immunol 1992; 148: 3700-3705.
30. Van Noesel C, Miedema F, Brouwer M, De Rie MA, Aarden LA, Van Lier RAW. Regulatory properties of LFA-1 alfa and beta chains in human T-lymphocyte activation. Nature 1988; 333: 850-852.
31. Marlin SD, Stauton DE, Springer TA. Stratowa C, Sommergruber W, Merluzzi VJ. A soluble form of intercellular adhesion molecule-1 inhibits rhinovirus infection. Nature 1990; 344: 70-72.
32. Kapp A. Elevated levels of soluble CD8 antigen in sera of patients with psoriasis-a possible sign of suppressor / cytotoxic T-cell activation. Arch Dermatol 1990; 282: 6-7.